open access

Vol 5, No 2 (2001)
Prace oryginalne
Published online: 2001-06-15
Get Citation

Costs of Hypertension in Poland

Tomasz Hermanowski, Rafał Jaworski, Marcin Czech, Robert Pachocki
Nadciśnienie tętnicze 2001;5(2):83-92.

open access

Vol 5, No 2 (2001)
Prace oryginalne
Published online: 2001-06-15

Abstract

Background The aim of the study was to assess costs related to hypertension in Poland. This analysis was carried out in GP’s centres throughout the country. The time horizon of the analysis was 12 months and a retrospective approach was applied. The direct medical costs of: pharmacological treatment, doctors’ consultations, laboratory and diagnostic tests and hospitalisations were identified and calculated. Indirect costs due to productivity loss were also included in the analysis. The cost assessment questionnaire was used to collect all the data concerning cost components.

Results The average cost per hypertensive patient per year was calculated at 1570 PLN. The total burden of hypertension in Poland, estimated on the basis of PENT study population analysis, may reach 14 billion PLN (14 ´ 109 PLN) per year. The distribution of total costs is as follows: pharmacological treatment — 10,2%, doctors’ consultations — 30,8%, laboratory and diagnostic tests — 11,4%, hospitalisations — 21,0%, and productivity losses — 26,6%. An international comparison demonstrated that expenditure resulting from the pharmacological treatment of hypertension in Poland was much smaller than in other countries (i.e. Sweden — 53,3%, and USA — 20,7%). Theoretically, the total societal burden of hypertension per resident per year amounts to 31 USD in Sweden, 82 USD in United States and 88 USD in Poland (according to the exchange rate on 21.01.2000 — 1 USD = 4,0757 PLN).

Conclusion The results of the analysis show that hypertension constitutes a high economic burden for the Polish population. The cost of pharmacological treatment represents the lowest percentage of the total costs of hypertension and also the lowest part of direct medical costs. The conclusion is that an optimal allocation of expenditure for pharmacological treatment may contribute to a significant reduction in total costs of hypertension following the example of other European countries (eg. Sweden) as well as the United States.

Abstract

Background The aim of the study was to assess costs related to hypertension in Poland. This analysis was carried out in GP’s centres throughout the country. The time horizon of the analysis was 12 months and a retrospective approach was applied. The direct medical costs of: pharmacological treatment, doctors’ consultations, laboratory and diagnostic tests and hospitalisations were identified and calculated. Indirect costs due to productivity loss were also included in the analysis. The cost assessment questionnaire was used to collect all the data concerning cost components.

Results The average cost per hypertensive patient per year was calculated at 1570 PLN. The total burden of hypertension in Poland, estimated on the basis of PENT study population analysis, may reach 14 billion PLN (14 ´ 109 PLN) per year. The distribution of total costs is as follows: pharmacological treatment — 10,2%, doctors’ consultations — 30,8%, laboratory and diagnostic tests — 11,4%, hospitalisations — 21,0%, and productivity losses — 26,6%. An international comparison demonstrated that expenditure resulting from the pharmacological treatment of hypertension in Poland was much smaller than in other countries (i.e. Sweden — 53,3%, and USA — 20,7%). Theoretically, the total societal burden of hypertension per resident per year amounts to 31 USD in Sweden, 82 USD in United States and 88 USD in Poland (according to the exchange rate on 21.01.2000 — 1 USD = 4,0757 PLN).

Conclusion The results of the analysis show that hypertension constitutes a high economic burden for the Polish population. The cost of pharmacological treatment represents the lowest percentage of the total costs of hypertension and also the lowest part of direct medical costs. The conclusion is that an optimal allocation of expenditure for pharmacological treatment may contribute to a significant reduction in total costs of hypertension following the example of other European countries (eg. Sweden) as well as the United States.

Get Citation

Keywords

hypertension; cost of illness; burden of disease; direct medical costs; indirect costs

About this article
Title

Costs of Hypertension in Poland

Journal

Arterial Hypertension

Issue

Vol 5, No 2 (2001)

Pages

83-92

Published online

2001-06-15

Bibliographic record

Nadciśnienie tętnicze 2001;5(2):83-92.

Keywords

hypertension
cost of illness
burden of disease
direct medical costs
indirect costs

Authors

Tomasz Hermanowski
Rafał Jaworski
Marcin Czech
Robert Pachocki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl